Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 12Lymphoma, Non-Hodgkin 7Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Recurrence 3Melanoma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Lymphoma, Follicular 2Cytokine Release Syndrome 2Craniopharyngioma 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × tocilizumab × 1 year × Clear all
NCT03448042 2026-05-28

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡